Upload
others
View
16
Download
0
Embed Size (px)
Citation preview
Public
Copyright © 2019 Covance. All Rights Reserved
NONCLINICAL CONSIDERATIONS FOR CELL & GENE THERAPIESBrian McIntosh, PhDPaul Byrne, PhD
March 11, 2019
Public
About Us
| Nonclinical Development Considerations for C&G Therapies2
Study Director for Safety Assessment/Toxicology in Madison, WI Trained with stem cell biologist Jamie Thomson and toxicologist Chris Bradfield
at the University of Wisconsin-Madison, and hematopoietic stem cell biologist Michael Cooke at the GNF (Novartis Institute) in San Diego
Subject matter expert in regenerative biology and the development of cellular, gene and regenerative therapies
Member: Covance’s Advanced Therapies Drug and Device Development Group
Principle Scientist for Cell and Gene Therapy, Bioanalytical and BioCMC in Harrogate
20+ years in the CRO industry including Study Director and Head of Molecular Biology
Member: Covance’s Advanced Therapies Drug and Device Development Group
•BRIAN E. McINTOSH, PhD
•PAUL BYRNE, PhD
Public
AGENDA
Today You’ll Hear About
| Nonclinical Development Considerations for C&G Therapies3
• How advanced therapies are defined• Preclinical study and regulatory/safety considerations and strategies when
assessing advance therapies• Analytical design and validation strategies• Biodistribution studies and data integrity• Titre assays• CMC considerations• Phase appropriate validations
Public
What type of Advanced Therapy
are you interested in advancing and where does your product fit?
| Nonclinical Development Considerations for C&G Therapies4
Public
Advanced Therapies: Cell vs Gene
| Nonclinical Development Considerations for C&G Therapies5
Cell-based Therapies(Regenerative Medicinal Products)
• Process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function– Function may be lost due to age,
disease, damage, or congenital defects – Regenerate damaged tissues and
organs in the body by stimulating previously irreparable organs to heal themselves
– Grow tissues and organs in the laboratory and safely implant
Gene Therapies
• Technique for correcting defective genes responsible for disease– Genes as medicine
• A normal gene may be inserted into a non-specific location within the genome to replace a non-functional gene– Viral vectors are the tool typically used to
deliver genetic material into cells– Vectors have included: adenoviruses, herpes
viruses, retroviruses, DNA tumor viruses, RNA tumor viruses, liposomes, and nanotechnology
Public
Preclinical Program Goals for Advanced Therapeutics
| Nonclinical Development Considerations for C&G Therapies6
• Data necessary to support development depends on the characteristics of the product
• Preclinical studies are designed to support use of a specific product for a specific clinical indication
• Identification of biologically relevant dose levels to guide clinical dose levels.
• Establish safety in relation to dose level of the clinical product.
• Identification of physiologic endpoints that can be used in the clinic for monitoring.
• Provide safety information to support first-in-human clinical trial.
Public
Preclinical Program Goals for Advanced Therapeutics (cont.)
| Nonclinical Development Considerations for C&G Therapies7
• Test system must be appropriate
• Species, disease models, immuno-deficient animals
• Autologous, allogeneic or xenogenic
• Delivery must represent clinical route of administration
• May include device compatibility
• Identity of test article/material is defined
• Identifying local and systemic toxicities following therapeutic administration
• Characterize potential adverse effects with respect to clinical dose, onset, duration
• Characterize derived therapy with respect to tumorigenicity, potential ectopic tissue formation
Public
•EXPEDITED PROGRAMS FOR REGENERATIVE MEDICINE THERAPIES FOR SERIOUS CONDITIONS
Fast Track and Breakthrough Designation Programs
| Nonclinical Development Considerations for C&G Therapies8
• Fast Track (designation) – for therapeutics intended to treat a serious condition where data demonstrate the potential to address an unmet medical need– Closer interaction with FDA on the drug development plan– Portions of the Marketing Application can be submitted in advance of the entire application, on a
“rolling review” basis• Breakthrough (designation) - for therapies intended to treat a serious condition
where preliminary clinical evidence indicates that the drug may demonstrate a substantial improvement over available therapies– All program features of Fast Track designation, including intensive guidance from FDA, to help
sponsors better tailor their drug development program– Organizational commitment from FDA’s senior managers and experienced review staff to
collaborate in advancing the review of these potentially high-impact drugs
Public
Issues to Overcome for In vivo Viral Delivery
| Nonclinical Development Considerations for C&G Therapies9
GENE THERAPY PRODUCTS
• Short Lived– Difficult to rapidly integrate therapeutic DNA into genome.– Rapidly dividing characteristic of certain cells may prevent long time efficacy– May require multiple rounds of therapy
• Immune Response– Foreign material introduced leads to immune response– Increased response when a repeat offender enters– AAV sero-negative screening in NHPs prior to study
• Vector Toxicity– Potential for toxic (gene over-expression), immune, inflammatory response– Potential to cause disease once administered
• Multigene Disorders– Difficult to treat conditions may require more than one gene
• Potential for Malignancy– Insertional mutagenesis may induce a tumor if integrated in a tumor suppressor gene
Public
Refresher Preclinical Study Considerations
| Nonclinical Development Considerations for C&G Therapies10
• Test system must be appropriate; may require pre-screen for neutralizing antibodies• Delivery must represent clinical route of administration• Test system may require immune suppression• Study length is dependent on therapeutic and clinical program: 7 days to 6 months• Delivery and virus dependent; shedding studies• Biodistribution/shedding: monitoring tissues for integration and fluids for infectious units• Efficacy assay to determine if the product was delivered and active• Pilot studies to optimize definitive study conditions• Identifying local and systemic toxicities following delivery• Characterize potential adverse effects with respect to clinical dose, onset, duration• Characterize derived GT with respect to potential tumor formation
GENE THERAPY PRODUCTS
Public
Preclinical Regulatory Considerations
| Nonclinical Development Considerations for C&G Therapies11
• Safety: acute, tumorigenicity, biodistribution, efficacy
• Open dialogue with the FDA-OTAT, EMA, PMDA…
EX VIVO DERIVED CELL THERAPY
Source: Fink. FDA Regulation of SC-Based Products. Science 2009;324:1662-63.
In vitro properties In vivo concerns
Public
Perspective Shifts in Early Development
| Nonclinical Development Considerations for C&G Therapies12
• Safety is primarily shifted to the manufacturing phase (CMC)– Personalized or individualized medicine – Variation in cell source– Limited production, small batch size– Establish minimal criteria to ensure safety efficacy and consistent production
• Assay development to evaluate ex vivo delivery system in relation to therapeutic– Tight control on copy number– Use of insulator elements in the payload– Use of self-inactivating viral vectors– Removal of unneeded/unwanted elements– Phenotype, generation of non-endogenous factors, genotype, karyotype
CAR-T THERAPY PRODUCTS
Public
Preclinical Study Considerations
| Nonclinical Development Considerations for C&G Therapies13
• A scientific discussion dictates in vivo safety designs• Controversy: definitive therapeutic is generally short-lived: beware of rise of the clone!
– Safety studies generally focus on long-term tumorigenicity: 3 to 6 months– Biodistribution 14 to 30 days (general lifetime of therapy)– In vitro assay measuring transformation/gain proliferative autonomy may be better measure
• Test system must be appropriate– Immunocompetent mammal would reject cells that were generated from a different species.– Immuno-deficient animals used.
• PDx or Syngenic models may be considered to generate data and be more relevant. • Future: Targeting solid tumors
– Generation of CAR2.0, CARs with kill switch, on/off switch controlled by small molecules, or other therapeutic interventions
CAR-T THERAPY PRODUCTS
Public
Preclinical Study Considerations
| Nonclinical Development Considerations for C&G Therapies14
• In vivo Tumorigenicity– Derived CBT/RMP dosed at varied concentrations to an ideally confined location in the
animal. – One group may be required for positive parental cell line or tumorigenic line
– (e.g. iPSC, MCF7, A498, PC3, Hep3B, etc.).
– Looking for ectopic tissue formation or potential migration.– Duration: minimum 3 months or to organism lifetime based on therapy/target population.
• Biodistribution assay– Quantitative PCR time course based analysis of major organs to monitor metastases.– Normally small animal (mouse or rat); may be performed via IHC– Duration:28-days to organism lifetime; time dependent on CBT/RMP target population– Can be in combination with tumorigenicity assay.
CELL THERAPY PRODUCTS
Public
Preclinical Study Considerations (cont.)
| Nonclinical Development Considerations for C&G Therapies15
• Acute/Efficacy/Dose Response– Employ disease or injury model test system– Adverse effects with respect to dose, onset, duration– Dependent on cellular response and physiology to detect signal and time course.– Combination: may be performed with biodistribution and/or tumorigenicity studies– Duration: may be 2 weeks up to 9 months
• Test article analysis– Viability – Compatibility with dosing apparatus – Characterization of cell type (flow)– Stability time course established: usually pre-dose and post-dose– GLP: pre-study validations required for enumeration, flow, antibody clones per cell type
CELL THERAPY PRODUCTS
Public
Closing remarks
| Nonclinical Development Considerations for C&G Therapies16
• Changing SA landscape with Cell and Gene Therapeutics
• Therapeutic dictates the study design
• Seek advice from a regulatory body and knowledgeable source prior to initiating work
• And the process is the product…
CELL AND GENE THERAPY STUDY DESIGNS
Public
| Nonclinical Development Considerations for C&G Therapies17
“What are the design considerations for bioanalytical assays to support
biodistribution studies?”
Public
Biodistribution Studies
| Nonclinical Development Considerations for C&G Therapies18
• Assay design is critical– Span the junction of modifications– Theoretical specificity– Feasibility– Multiple applications
– CMC– Clinical
• Validation considerations– LOQ, LOD, Linearity, Range, Specificity, Inhibition, Robustness,
Precision and Stability
QPCR / RT-QPCR ASSAY DESIGN CONSIDERATIONS
Biodistribution
Toxicology
Public
Biodistribution Studies
| Nonclinical Development Considerations for C&G Therapies19
• Sensitivity is critical – LOQ – 50 copies / µg of genomic DNA
– Chemistry is important – e.g. TaqMan or SYBR Green
• Specificity– Importance of assay design
• Extraction considerations– Challenge selections of tissues, biofluids and blood– Recovery of plasmid/vector/stem cell DNA
– 50%-80% (20%-80% recovery)
•QPCR ASSAY DESIGN CONSIDERATIONS
Biodistribution
Toxicology
Public
| Nonclinical Development Considerations for C&G Therapies20
“What are the key analytical and design considerations for preclinical
biodistribution studies?”
Public
Biodistribution Studies
| Nonclinical Development Considerations for C&G Therapies21
• Combined with toxicology study: separate biodistribution groups/ cohorts• Route of administration: dependent on therapy• Timepoints – 1wk, 1M and 3M• Assessment of distribution and persistence of vector/cell
– Tissues– Depends on route and MOA
– Blood– Biofluids
– Viral shedding• DNA and transgene (mRNA) expression• Focus on preventing contamination
•QPCR ASSAY DESIGN CONSIDERATIONS
Biodistribution
Toxicology
Dispensary AnimalRoom Necropsy Extraction qPCR
Analyses
Public
Biodistribution Studies
| Nonclinical Development Considerations for C&G Therapies22
Biodistribution
Toxicology
Dispensary
Animalroom
Necropsy
Extraction
qPCRAnalyses
Sterile, biological handlingSpecific procedures and aliquots
Specialized dosingHandling, separation and housing
Precautions and proceduresDisposable equipment and sample collection
Purpose build laboratoriesAutomated high throughput and controls
PCR clean areasHigh throughput and controls
Public
Biodistribution Studies - Responsibilities
| Nonclinical Development Considerations for C&G Therapies23
Biodistribution
Toxicology
Dispensary
Animalroom
Necropsy
Extraction
qPCRAnalyses
Sterile, biological handlingSpecific procedures and aliquots
Specialized dosingHandling, separation and housing
Precautions and proceduresDisposable equipment and sample collection
Purpose build laboratoriesAutomated high throughput and controls
PCR clean areasHigh throughput and controls
SME SD PI
Public
Biodistribution Studies
| Nonclinical Development Considerations for C&G Therapies24
• Significant risks for compromised studies– Cost of repeats– Delays to submissions– Impact to clinical trial design
• Important to have alignment between in-life, necropsy and analytical– Sample collection
– Guided by analytical team– Handling, storage and shipping
– Sample management, labels and barcodes– Reporting and analytical validation
– Collaboration between SD and PI
CONFIDENCE IN DATA
Biodistribution
Toxicology
Public
Biodistribution Studies
| Nonclinical Development Considerations for C&G Therapies25
• CMC Information for Human Gene Therapy Investigational INDs –FDA Draft Guidance for Industry, July 2018
– Ensure ability to compare the preclinical dose to the clinical dose– Use the same qualified method to quantitate preclinical and clinical lots
• Human Gene Therapy for Hemophilia –FDA Draft Guidance for Industry, July 2018
• The assay for vector titre determination of the preclinical lots should be identical to the assay used for clinical lots
• QPCR or ddPCR?
TITRE / DOSE DETERMINATION
Biodistribution
Toxicology
Public
| Nonclinical Development Considerations for C&G Therapies26
“What questions do you need to address to ensure safety, efficacy and consistency for
IND/IMPD submissions?”
Chemistry, Manufacturing and Controls (CMC)
Public
Critical Quality Attributes
| Nonclinical Development Considerations for C&G Therapies27
• How much do you have?• How potent is it?• How safe is it?• How pure is your product?• Is it what you think it is?• Is it stable?
CMC
CMC
Clinical
Public
How Much Do You Have?
| Nonclinical Development Considerations for C&G Therapies28
Part 1 – retroviral/lentiviral vectorPart 2 – active substance (CAR-T)
CRITICAL QUALITY ATTRIBUTES
CMC
Clinical
AAV Vectors CAR-TPart 1 Part 2
Genomic Titre (QPCR) Vector titre (QPCR) Viability (Flow)Capsid Titre (ELISA) Cell count (Flow)
Quantity and Titre
Public
How Potent Is It?
| Nonclinical Development Considerations for C&G Therapies29
CRITICAL QUALITY ATTRIBUTES
CMC
Clinical
AAV Vectors CAR-TPart 1 Part 2
Cell-based assay with ELISA endpoint
PBMC transduction Cell based assay with ELISA endpoint
Infectious titre (cell-based QPCR endpoint)
Transduction efficiency (QPCR)
CAR expression (flow)
Biological Activity, Transduction and Potency
Public
How Safe Is It?
| Nonclinical Development Considerations for C&G Therapies30
CRITICAL QUALITY ATTRIBUTES
CMC
Clinical
AAV Vectors CAR-TPart 1 Part 2
Safety testing ICH Q5A Safety testing ICH Q5A
Sterility
rcAAV RCR/RCL Mycoplasma
Endotoxin
Safety Testing
Public
How Pure Is It?
| Nonclinical Development Considerations for C&G Therapies31
CRITICAL QUALITY ATTRIBUTES
CMC
Clinical
AAV Vectors CAR-TPart 1 Part 2
Host Cell Proteins and DNA(ELISA and QPCR)
HCP and HCDNA (ELISA and QPCR)
Vector (QPCR)
BSA, Benzonase (ELISA) RCR/RCL Beads (Microscopy)
Capsid purity (CE)
Empty vs full
Purity and Impurities
Public
Is It What You Think It Is?
| Nonclinical Development Considerations for C&G Therapies32
CRITICAL QUALITY ATTRIBUTES
CMC
Clinical
AAV Vectors CAR-TPart 1 Part 2
Sequencing, Mass Spec Sequencing QPCR
Identity
Public
| Nonclinical Development Considerations for C&G Therapies33
“How can I rely on the data for submission, and what does a phase appropriate
validation plan look like?”
Public
Regulatory perspective
| Nonclinical Development Considerations for C&G Therapies34
• CMC Information for Human Gene Therapy Investigational INDs –FDA Draft Guidance for Industry, July 2018
– Validation not required for IND phase 1– Appropriately controlled
– Complete validation before BLA– Evaluate performance through development– Have a plan in place
– Consistent with European guidance
VALIDATIONS
Biodistribution
Toxicology
Public
Development Pathway
| Nonclinical Development Considerations for C&G Therapies35
CMC
Product Understanding
PreclinicalPhase I
Phase IIPhase III
Commercial
BLA / MAA IND / IMPD
CMC: Validation
Public
Assay Validation
| Nonclinical Development Considerations for C&G Therapies36
Fit for purpose / controlled / suitability• Compendial
– 1 run to qualify (additional for small volumes)• Identity / Purity (QPCR, ELISA, CE-SDS, MS, FACS)
– 2-3 runs• Titre (QPCR, ELISA)
– 3-4 runs• Potency (Cell based)
– 15 runs
DEFINITIONS
CMC
Public
Assay Validation
| Nonclinical Development Considerations for C&G Therapies37
Limited validation• Identity / Purity / Titre (QPCR, ELISA, CE-SDS, MS)
– 7-8 runs• Potency (cell-based)
– 9 runsFull validation (robustness)
– Design of experiment (DOE)– 8 runs– QPCR included with limited validation
DEFINITIONS
CMC
Public
Validation Pathway
| Nonclinical Development Considerations for C&G Therapies38
CMC
Phase IPhase II
Phase IIICommercial
Validation requirement
Compendial
Fit for purpose
Public
Validation Pathway
| Nonclinical Development Considerations for C&G Therapies39
CMC
Phase IPhase II
Phase IIICommercial
Validation requirement
Identity / Purity / Potency
Fit for purpose Limited validation Full validation
Limited validation Full validation
Public
Validation Pathway
| Nonclinical Development Considerations for C&G Therapies40
CMC
Phase IPhase II
Phase IIICommercial
Validation requirement
Titre Assays
Fit for purpose Limited validation Full validation
Preclinical??Full validation
Public
Copyright © 2019 Covance. All Rights Reserved